Inventor
MYERS MICHAEL R
US43 patents
⚠️ This page may combine multiple inventors who share the name “MYERS MICHAEL R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
RHONE POULENC RORER PHARMA
14 patentsUSRE36256EJul 20, 1999
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
RHONE POULENC RORER PHARMA183 citations99
US5721237AFeb 24, 1998
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
RHONE POULENC RORER PHARMA245 citations99
US5710158AJan 20, 1998
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
RHONE POULENC RORER PHARMA339 citations99
US5656643AAug 12, 1997
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
RHONE POULENC RORER PHARMA258 citations99
US5646153AJul 8, 1997
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
RHONE POULENC RORER PHARMA259 citations99
US5561134AOct 1, 1996
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
RHONE POULENC RORER PHARMA143 citations99
US5480883AJan 2, 1996
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
RHONE POULENC RORER PHARMA383 citations99
US5736554AApr 7, 1998
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
RHONE POULENC RORER PHARMA102 citations98
US5714493AFeb 3, 1998
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
RHONE POULENC RORER PHARMA176 citations98
US5364862ANov 15, 1994
Compounds having antihypertensive and anti-ischemic properties
RHONE POULENC RORER PHARMA141 citations98
US5409930AApr 25, 1995
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
RHONE POULENC RORER PHARMA314 citations97
US5795889AAug 18, 1998
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
RHONE POULENC RORER PHARMA59 citations96
US5652366AJul 29, 1997
DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
RHONE POULENC RORER PHARMA93 citations94
US5476851ADec 19, 1995
Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
RHONE POULENC RORER PHARMA25 citations91
AVENTIS PHARMA INC
11 patentsUS6528526B1Mar 4, 2003
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARMA INC305 citations99
US6524347B1Feb 25, 2003
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARMA INC307 citations99
US6482834B2Nov 19, 2002
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARMA INC254 citations99
US6645969B1Nov 11, 2003
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
AVENTIS PHARMA INC74 citations95
US6846815B2Jan 25, 2005
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARMA INC28 citations93
US6696434B2Feb 24, 2004
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARMA INC14 citations93
US6376472B1Apr 23, 2002
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
AVENTIS PHARMA INC24 citations92
US6852712B2Feb 8, 2005
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARMA INC3 citations63
US6821962B2Nov 23, 2004
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases
AVENTIS PHARMA INC2 citations63
US7612075B2Nov 3, 2009
Substituted oxoazaheterocyclyl compounds
AVENTIS PHARMA INC3 citations60
US7550597B2Jun 23, 2009
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARMA INC0 citations52
AVENTIS PHARMA SA
7 patentsUS6479479B2Nov 12, 2002
Azetidine derivatives, their preparation and pharmaceutical compositions containing them
AVENTIS PHARMA SA81 citations97
US6355631B1Mar 12, 2002
Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
AVENTIS PHARMA SA107 citations97
US6734176B2May 11, 2004
Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AVENTIS PHARMA SA47 citations96
US6566356B2May 20, 2003
Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AVENTIS PHARMA SA60 citations96
US6872717B2Mar 29, 2005
Pharmacological uses of azetidine derivatives
AVENTIS PHARMA SA35 citations92
US7132414B2Nov 7, 2006
Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AVENTIS PHARMA SA9 citations73
US7741316B2Jun 22, 2010
Pharmacological uses of azetidine derivatives
AVENTIS PHARMA SA0 citations52
AVENTIS PHARM PROD INC
4 patentsUS6245760B1Jun 12, 2001
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARM PROD INC257 citations99
US6180632B1Jan 30, 2001
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARM PROD INC395 citations99
US6159978ADec 12, 2000
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AVENTIS PHARM PROD INC203 citations99
US6057320AMay 2, 2000
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AVENTIS PHARM PROD INC148 citations99